乳酸菌对高脂血症小鼠血脂和肠道菌的影响

关键词：乳酸菌  胆固醇  甘油三酯  肠道菌

Keywords:Lactobacillus  cholesterol  triglyceride  gut flora

摘要：

      摘要 目的：研究功能乳酸菌制剂的降血脂作用及对肠道菌的影响。 方法：建立小白鼠高脂血症动物模型；模型小鼠30只，随机分为：生理盐水组、复合乳酸菌组和辛伐他汀组，每组10只。采取灌胃处理，分别灌服生理盐水、复合乳酸菌制剂（等比例混合的植物乳杆菌、嗜酸乳杆菌和干酪乳杆菌）和降血脂药物辛伐他汀。 结果：与生理盐水比较，乳酸菌和辛伐他汀药物处理显著降低了小鼠血清胆固醇（TC）、甘油三酯（TG）和低密度脂蛋白胆固醇（HDL-C）含量（P＜0.05）；乳酸菌处理和药物处理间TC、TG和HDL-C无显著差异。与降血脂药物相比，乳酸菌处理显著增加小鼠粪便乳酸菌数量（P＜0.05），降低了大肠杆菌（P＜0.05）和肠球菌数量（P＜0.01）。 结论：乳酸菌制剂具有降低血脂、增加肠道有益菌数量、降低肠道有害菌数量的作用。

Abstract:

      Abstract Objective: To test the effects of natural lactobacillus bio-products on lipid metabolism and intestinal microflora. Method: A hyperlipidemia mouse model system was developed. 30 hyperlipidemia mice were randomly divided into three equal groups, i.e, saline water (control treatment), lactobacillus cocktail, and simvastatin. Mice were injected daily with saline water, lactobacillus (L. plantarum, L. acidophilus and L. casei, mixture in equal volume), and simvastatin solution, respectively. Result: Significant lower total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were found in the blood serum from mice treated with lactobacillus and pharmaceutical simvastatin. CFUs (colony forming unity) of lactobacillus were much higher (P＜0.05), whereas CFUs of Escherichia coli and Enterococcus faecalis were much lower (P＜0.05 and P＜0.05, respectively) in mice feces of treated by lactobacillus compared to pharmaceutical simvastatin. Conclusion: Lactobacillus probiotics reduced levels of cholesterolemia, increased CFUs of lactobacillus and reduced CFUs of E. coli and E. faecalis in gut.